Explore new data, expert perspectives, and innovations in heart valve surgery

Join us at the American Association for Thoracic Surgery (AATS) annual meeting for expert-led lunch and evening symposia. Discover the latest real-world evidence on the KONECT RESILIA aortic valved conduit, gain insights into mitral valve lifetime management, and explore the RESILIA tissue portfolio at our booth.

What you need to know for mitral valve lifetime management

Durability, EOAs, and the MITRIS RESILIA valve.

Lunch Symposium 

Friday, May 2nd 

12:00 PM — 1:00 PM

Rooms: 447-448, Level 4

Agenda:

• Should mitral valve replacement age guidelines be lowered due to better bioprosthetic mitral valve durability?
• Hemodynamic comparison of two models of bioprosthetic mitral valves under standardized in vitro conditions
• Comparative differences based on mitral valve-in-valve implantation in an animal model
• The mitral valve developed with your patient's quality of life in mind

Speakers are paid consultants of Edwards Lifesciences.
To attend this symposium, you must be a registered attendee of the AATS 105th Annual Meeting.

Connecting the latest data to the first pre-assembled aortic tissue valved conduit

KONECT device—ready to implant.^* Learn the techniques.

Evening Symposium 

Saturday, May 3rd  

6:15 PM — 7:15 PM

Room: Elwha Ballroom, Hyatt Regency, Level 5

Agenda:

• Data from The Cleveland Clinic Foundation, The Hospital of the University of Pennsylvania and Weill Cornell Medical Center
• Techniques for a simplified approach to root replacement from Dr. Bavaria
• Techniques for a Bio-Bentall procedure by Dr. Lawrence

Speakers are paid consultants of Edwards Lifesciences.
*Consult instructions for use for device preparation instructions.
To attend this symposium, you must be a registered attendee of the AATS 105th Annual Meeting.

Refer to the below tables for presentation time slots:

Edwards Lifesciences is advancing the future of cardiac surgery through collaboration with surgical experts and creating a portfolio of valves designed with RESILIA tissue. Today's RESILIA tissue portfolio reflects the result of scientific partnership and innovation, addressing unmet needs and satisfying patient demands for better surgical options. 

Can’t wait? Start learning more. 

Important Safety Information: RESILIA Tissue Devices

 

Indications: INSPIRIS RESILIA Aortic Valve - For use in replacement of native or prosthetic aortic heart valves. KONECT RESILIA Aortic Valved Conduit - For use in replacement of native or prosthetic aortic heart valves and the associated repair or replacement of a damaged or diseased ascending aorta. MITRIS RESILIA Mitral Valve – For use in replacement of native or prosthetic mitral heart valves.

 

Contraindications: There are no known contraindications with the use of these RESILIA tissue heart valve devices.

 

Complications and Side Effects: INSPIRIS RESILIA Aortic Valve - Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, any of which could lead to reoperation, explantation, permanent disability, and death. Additional adverse events potentially associated with the use of polyester vascular grafts in the KONECT RESILIA AVC include hemorrhage, thrombosis, graft infection, embolism, aneurysm, pseudoaneurysm, seroma, occlusion (anastomotic intimal hyperplasia), immunological reaction to collagen (shown to be a weak immunogen; infrequent, mild, localized and self-limiting), intimal peel formation, and conduit dilatation. MITRIS RESILIA Mitral Valve -Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, ventricular perforation by stent posts, any of which could lead to reoperation, explantation, permanent disability, and death.

 

Warnings: INSPIRIS RESILIA Aortic Valve - DO NOT ADJUST THE VALVE DIAMETER BY EXPANDING THE BAND PRIOR TO OR DURING IMPLANTATION OF THE SURGICAL VALVE. The expandable band is not designed to allow for compression or expansion during implantation of the surgical valve. This will cause damage to the valve and may result in aortic incompetence. DO NOT PERFORM STAND-ALONE BALLOON AORTIC VALVULOPLASTY PROCEDURES ON THIS VALVE FOR THE SIZES 19 – 25 mm as this may expand the valve causing aortic incompetence, coronary embolism or annular rupture. Valve-in-valve sizing in the INSPIRIS valve has only been tested with specific Edwards transcatheter heart valves. Use of other transcatheter valves may result in embolization of transcatheter devices anchored within or result in annular rupture.

 

CAUTION: Federal (USA) law restricts these devices to sale by or on the order of a physician. See Instructions for Use for full prescribing information.

 

These industry symposiums will be held in conjunction with the AATS Annual Meeting. It is not part of the official AATS scientific program. Continuing Medical Education (CME) credit for this activity is not offered by AATS.

Edwards, Edwards Lifesciences, the stylized E logo, COMMENCE, INSPIRIS, INSPIRIS RESILIA, KONECT, KONECT RESILIA, MITRIS, MITRIS RESILIA, and RESILIA are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.